Aug 08, 2018
Teva’s migraine drug is expected to launch this year despite the delay in FDA approval Teva Pharmaceutical’s fremanezumab for treating migraine is expected to launch later this year. Celltrion disclosed that U.S. drug regulators issued a Form 483 for its plant in Incheon, South Korea on tuesdsy. Eight manufacturin...
Read More...
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Mar 06, 2026
BYSANTI Approval Positions Vanda to Compete in the Antipsychotic Market
Mar 02, 2026
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper